Casodex
Designed to target tumour growth, indicated to manage advanced prostate cancer effectively.
Strengths: 50mg
Where to Check Availability
Medicine details
- Conditions
- Therapeutic class
Anti-Androgen
- Pharmacological class
Non-steroidal Anti-Androgen
- Contraindications
hypersensitivity to bicalutamide; pregnancy; women
- Precautions and warnings
monitor liver function regularly; not indicated for use in children
- Minor side effects
hot flushes; nausea; fatigue; constipation
- Moderate side effects
gynaecomastia; breast tenderness; elevated liver enzymes
- Dosage forms
Film-coated tablet
- Administration route
Oral use
- Prescription status
POM
- Manufacturer
AstraZeneca
- Onset Time
4–8 weeks
- Duration
24 hours
- Storage instructions
Store below 30°C.
- Drug interactions
warfarin; ciclosporin
- Age restrictions
Not for use in patients under 18.
- Pregnancy and breastfeeding
Pregnancy: Not applicable (contraindicated). Breastfeeding: Not applicable.
Serious side effects
hepatitis — requires immediate medical attention; cholestasis — requires immediate medical attention
Patient summary
Designed to target tumour growth, indicated to manage advanced prostate cancer effectively.
Mechanism of action
Bicalutamide is a non-steroidal anti-androgen that binds to the androgen receptor. It prevents the binding of testosterone and dihydrotestosterone, thereby inhibiting the growth and progression of androgen-sensitive prostate cancer cells.
Casodex
Designed to target tumour growth, indicated to manage advanced prostate cancer effectively.
Editorial Notes
- Active ingredient(s): Bicalutamide
- Listed indication(s): Advanced Prostate Cancer
Available option
- 30 tablets - 50 mg591-50-mg-910